Related Experiment Video

Updated: Jun 4, 2025

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat
07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus MRSA in Rat

Published on: June 4, 2012

15.7K

Treatment of Complicated Gram-Positive Bacteremia and Infective Endocarditis

Paul Schellong1,2, Oana Joean3, Mathias W Pletz3

  • 1Institute for Infectious Disease and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Am Klinikum 1, 07749, Jena, Germany. paul.schellong@med.uni-jena.de.

Drugs
|December 25, 2024
PubMed

Insights

Complicated bacteremia, often caused by Staphylococcus aureus, requires extended antimicrobial therapy and source control. This review details management, diagnostics, and treatment for these serious bloodstream infections, focusing on infective endocarditis.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Cardiology

Background:

  • Gram-positive cocci like Staphylococcus aureus, Streptococcus spp., and Enterococcus spp. are primary causes of bloodstream infections and infective endocarditis.
  • Complicated bacteremia, initially defined by metastatic foci in Staphylococcus aureus infections, necessitates prolonged antimicrobial treatment and source control.

Purpose of the Study:

  • To review current management, diagnostic strategies, and treatment options for complicated bacteremia.
  • To provide a focused discussion on infective endocarditis in the context of complicated bacteremia.

Main Methods:

  • Review of existing literature on diagnostic modalities and antimicrobial therapies.
  • Synthesis of evidence regarding treatment durations, administration routes, and pathogen resistance patterns.

Main Results:

  • Identified risk factors for bacteremia complications inform the definition of complicated bacteremia.
  • Evidence summarized for imaging, antimicrobial choice (mono- vs. combination therapy), and optimized treatment protocols.

Conclusions:

  • Complicated bacteremia requires a comprehensive approach involving diagnostics, source control, and tailored antimicrobial therapy.
  • Further research into complicated bacteremia and infective endocarditis is warranted to optimize patient outcomes.

More Related Videos

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials06:18

A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials

Published on: March 3, 2023

1.3K
Intravitreal Injection and Quantitation of Infection Parameters in a Mouse Model of Bacterial Endophthalmitis07:24

Intravitreal Injection and Quantitation of Infection Parameters in a Mouse Model of Bacterial Endophthalmitis

Published on: February 6, 2021

11.2K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
298
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.7K
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
326
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
153
Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
103